Intravenous Sildenafil in the Treatment of Neonates with Persistent Pulmonary Hypertension - 07/08/11
, John P. Kinsella, MD b, Christine Pierce, MD c, Ghazwan Butrous, MB, PhD d, Maria Dilleen, MSc e, Michael Oakes, MSc, PhD e, David L. Wessel, MD f
Reprint requests: Robin H. Steinhorn, MD, Children’s Memorial Hospital, 2300 Children’s Plaza, Box 45, Chicago, IL 60614.Abstract |
Objective |
To evaluate the safety of intravenous (IV) sildenafil, an inhibitor of cyclic guanosine monophosphate–specific phosphodiesterase, in treating near-term and term newborns with persistent pulmonary hypertension of the newborn (PPHN).
Study design |
This was an open-label, dose-escalation trial in newborns with PPHN and an oxygenation index (OI) > 15. Sildenafil was delivered by continuous IV infusion for at least 48 hours and up to 7 days.
Results |
Five centers enrolled a total of 36 neonates with PPHN at a mean of 34 ± 17 hours of age; 29 of these neonates were already receiving inhaled nitric oxide (iNO). A significant improvement in OI (28.7 to 19.3; P = .0002) was observed after 4 hours of sildenafil infusion in the higher dose cohorts. Thirty-five neonates survived; 1 neonate required extracorporeal membrane oxygenation (ECMO) support. In 4 neonates, sildenafil was stopped due to adverse events. Seven neonates were enrolled before developing the need for iNO. In these neonates, OI improved significantly by 4 hours after initiation of sildenafil infusion (24.6 to 14.7; P = .009); 6 neonates completed treatment without the need for iNO or ECMO.
Conclusions |
IV sildenafil was well tolerated, and acute and sustained improvements in oxygenation were noted in those neonates who received the higher infusion doses.
Le texte complet de cet article est disponible en PDF.Mots-clés : cAMP, cGMP, ECMO, FiO2, iNO, IV, OI, PaO2, PDE5, PPHN
Plan
| The study sponsor (Pfizer) provided the intravenous sildenafil, financial support for the clinical research nurse and other costs of conducting the study at each site, as well as ongoing site monitoring. The data analysis was performed by the academic authors and reviewed by statisticians who are employees of Pfizer (M.D. and M.O.). The manuscript was prepared by R.H.S., G.B., and J.P.K. No honorarium or other payment was provided to produce the manuscript. |
Vol 155 - N° 6
P. 841 - décembre 2009 Retour au numéro
Article précédent
- Long-term Clinical Outcome of Patients with Severe Combined Immunodeficiency Who Received Related Donor Bone Marrow Transplants without Pretransplant Chemotherapy or Post-transplant GVHD Prophylaxis
- Mary Dell Railey, Yuliya Lokhnygina, Rebecca H. Buckley
- Segmental Brain Volumes and Cognitive and Perceptual Correlates in 15-Year-Old Adolescents with Low Birth Weight
- Marit Martinussen, Dana W. Flanders, Bruce Fischl, Evelina Busa, Gro C. Løhaugen, Jon Skranes, Torgil R. Vangberg, Ann-Mari Brubakk, Olav Haraldseth, Anders M. Dale
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?